Highly Efficacious Treatment for Hepatitis C Virus (HCV) by Disrupting its Replication
A more thorough understanding of HCV has led to the development of treatment like Direct Acting Antiviral (DAA), which targets specific non-structural proteins in the virus and disrupts its replicating and infecting capabilities. Compared to existing remedies, DAA-based treatments provide a higher cure rate, fewer side effects, and reduce the length of therapy by up to four times. A major challenge to this treatment are HCV patients that are also affected by HIV and/or those who have a history of alcohol and drug abuse.
The aim of this study is to establish a minimal cost model for Nepal, based on findings from the original research protocol. Patient care will be managed via a community-based model in order to minimize hospital resources. Also, laboratory follow up will be conducted at key time points while ensuring an excellent safety profile and minimal toxicity at all times.